Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Developing and Strengthening Cannabis Warnings: Warning Message Testing

8. juli 2026 oppdatert av: University of North Carolina, Chapel Hill
The purpose of this activity is to identify promising cannabis warning messages from different themes. Participants will be adults who live in the United States, including both people who use cannabis and those who do not use cannabis. In an online within-subjects experiment, participants will be randomly assigned to view 7 cannabis warning messages from different themes developed as part of previous study activities. After viewing each cannabis warning message, participants will rate the message on awareness, clarity, believability, cognitive elaboration, perceived message effectiveness, and reactance. The survey will take 15-20 minutes.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The purpose of this activity is to identify promising cannabis warning messages from different themes.

Setting: An online survey of adults who live in the United States.

Participants: An estimated N=1500 adults who live in the United States, including both people who use cannabis and those who do not use cannabis. Participants will be recruited by Qualtrics Services. Participants who are eligible for the study will view a consent form as part of the survey and check a box to indicate that they agree to participate in the study. Once the participant has completed consent, they will be able to begin the survey.

Procedures: Participants will complete a within-subjects experiment in which they view and rate cannabis warning messages from different themes. Participants will be screened for inclusion and answer questions on demographic information and susceptibility to cannabis use. Participants will then be randomly assigned to view 7 cannabis warning messages from different themes developed as part of previous study activities. After viewing each cannabis warning message, participants will rate the message on awareness, clarity, believability, cognitive elaboration, perceived message effectiveness, and reactance. There will be a total of 11 warning themes plus control. After viewing and rating their assigned cannabis warning messages, participants will answer additional questions about cannabis risk perceptions and use behavior (if applicable), additional demographic information, and about their use of tobacco and alcohol. The survey will take 15-20 minutes.

Studietype

Intervensjonell

Registrering (Antatt)

1500

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Sarah D Kowitt, PhD, MPH
  • Telefonnummer: 919-974-4980
  • E-post: kowitt@unc.edu

Studiesteder

  • Forente stater
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27514
        • University of North Carolina at Chapel Hill
        • Ta kontakt med:
          • Sarah D Kowitt, PhD, MPH
          • Telefonnummer: 919-974-4980
          • E-post: kowitt@unc.edu

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Age 18 years of age and older
  • Live in the United States

Exclusion Criteria:

  • Age less than 18 years of age
  • Does not live in the United States

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Cannabis warning messages

Participants will view and rate 7 cannabis warning messages. The cannabis warning messages cover 11 different themes plus a control theme and were identified in a previous study activity.

Theme 1: Constituents Theme 2: Cognitive Functioning Theme 3: Cardiovascular Health Theme 4: Motor Vehicle Crashes Theme 5: Dependence Theme 6: Psychosis and Schizophrenia Theme 7: Mental Health Theme 8: Reproductive Health Theme 9: Respiratory Health Theme 10: Edibles Theme 11: Cannabis Hyperemesis Syndrome Theme 12: Control
Atferdsmessig: Constituents
Participants will view and rate a message about constituents.
Atferdsmessig: Cognitive Functioning
Participants will view and rate a message about cognitive functioning.
Atferdsmessig: Cardiovascular Health
Participants will view and rate a message about cardiovascular health.
Atferdsmessig: Motor Vehicle Crashes
Participants will view and rate a message about motor vehicle crashes.
Atferdsmessig: Dependence
Participants will view and rate a message about dependence.
Atferdsmessig: Psychosis and Schizophrenia
Participants will view and rate a message about psychosis and schizophrenia.
Atferdsmessig: Mental Health
Participants will view and rate a message about mental health.
Atferdsmessig: Reproductive Health
Participants will view and rate a message about reproductive health.
Atferdsmessig: Respiratory Health
Participants will view and rate a message about respiratory health.
Atferdsmessig: Edibles
Participants will view and rate a message about edibles.
Atferdsmessig: Cannabis Hyperemesis Syndrome
Participants will view and rate a message about cannabis hyperemesis syndrome.
Atferdsmessig: Control
Participants will view and rate a control message.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cognitive Elaboration
Tidsramme: Baseline (one time online survey)
A one item measure of cognitive elaboration to assess how much a message makes the participant think about the health risks of cannabis. Response options are on a 5-point scale from 5='A great deal' to 1= 'Not at all', with higher scores indicating higher cognitive elaboration.
Baseline (one time online survey)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Perceived Message Effectiveness
Tidsramme: Baseline (one time online survey)
This survey item assesses perceived message effectiveness in terms of how concerned the message makes the participant feel about the health effects of using cannabis. Response options are on a 5-point scale from 5='A great deal' to 1='Not at all' with higher scores indicating higher perceived message effectiveness.
Baseline (one time online survey)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Clarity
Tidsramme: Baseline (one time online survey)
This survey item assesses the extent to which a participant feels that the message is clear. Response options are on a 5-point scale from 5='Very clear' to 1='Not clear at all' with higher scores indicating that a message is more clear.
Baseline (one time online survey)
Believability
Tidsramme: Baseline (one time online survey)
This survey item assesses the extent to which a participant feels that the message is believable. Response options are on a 5-point scale from 5='Very believable' to 1='Not at all believable' with higher scores indicating that a message is more believable.
Baseline (one time online survey)
Reactance
Tidsramme: Baseline (one time online survey)
This survey item assesses reactance in terms of how much a participant is annoyed by the message. Response options are on a 5-point scale from 5='A great deal' to 1='Not at all' with higher scores indicating higher reactance to the message.
Baseline (one time online survey)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

University of North Carolina, Chapel Hill

Samarbeidspartnere

National Institute on Drug Abuse (NIDA)

Etterforskere

  • Hovedetterforsker: Sarah D Kowitt, PhD, MPH, University of North Carolina, Chapel Hill
  • Hovedetterforsker: Leah M Ranney, PhD, MA, University of North Carolina, Chapel Hill

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

13. juli 2026

Primær fullføring (Antatt)

30. november 2026

Studiet fullført (Antatt)

30. november 2026

Datoer for studieregistrering

Først innsendt

25. juni 2026

Først innsendt som oppfylte QC-kriteriene

8. juli 2026

Først lagt ut (Faktiske)

13. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. juli 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 24-1616
  • R01DA058003 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

A de-identified version of individual participant data will be shared through the UNC Dataverse

IPD-delingstidsramme

The dataset will be available after data collection and analysis and will remain available for 10 years

Tilgangskriterier for IPD-deling

Open Access

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere